HOTH
Closed
Hoth Therapeutics Inc
1.22
+0.05 (+4.27%)
Last Update: 01 Jul 2025 23:17:00
Yesterday: 1.17
Day's Range: 1.15 - 1.22
Send
sign up or login to leave a comment!
When Written:
2.0639
Hoth Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the development of therapies for dermatological disorders. The company was founded in 2017 and is headquartered in New York City.
Hoth Therapeutics is developing a pipeline of novel therapeutics that target a range of skin diseases, including atopic dermatitis, psoriasis, and acne. The company's lead product candidate is a topical cream called BioLexa, which is designed to treat skin inflammation and infections.
In addition to BioLexa, Hoth Therapeutics is also developing other product candidates, including HT-003, a topical cream for the treatment of psoriasis, and HT-004, a topical cream for the treatment of acne.
Hoth Therapeutics has partnerships with a number of academic institutions, including the George Washington University and the University of Maryland, to develop and commercialize its product candidates. The company has also received funding from the National Institutes of Health and the National Science Foundation to support its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Hoth Therapeutics is developing a pipeline of novel therapeutics that target a range of skin diseases, including atopic dermatitis, psoriasis, and acne. The company's lead product candidate is a topical cream called BioLexa, which is designed to treat skin inflammation and infections.
In addition to BioLexa, Hoth Therapeutics is also developing other product candidates, including HT-003, a topical cream for the treatment of psoriasis, and HT-004, a topical cream for the treatment of acne.
Hoth Therapeutics has partnerships with a number of academic institutions, including the George Washington University and the University of Maryland, to develop and commercialize its product candidates. The company has also received funding from the National Institutes of Health and the National Science Foundation to support its research and development efforts.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!